Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Cefomax** is a fixed-dose injectable antibacterial combination of the third-generation cephalosporin **ceftriaxone** and the beta-lactamase inhibitor **sulbactam**. The Maxx Pharm product contains ceftriaxone 1 g and sulbactam 500 mg per vial as powders for preparation of an intravenous or intramuscular solution. Ceftriaxone is bactericidal through inhibition of bacterial cell-wall synthesis, while sulbactam irreversibly inhibits susceptible bacterial beta-lactamases and can restore or enhance ceftriaxone activity against beta-lactamase-producing organisms. Maxx Pharm markets the product for susceptible bacterial infections, including urinary tract, intra-abdominal, lower respiratory tract, ear-nose-throat, skin and soft-tissue, bone and joint, genital tract, and central nervous system infections, as well as perioperative infection prophylaxis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ceftriaxone + sulbactam (Max Pharma).